Press Releases Press Releases Year None20222021202020192018201720162015 Jul 25, 2022 InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa Jul 18, 2022 InMed Announces Appointment of Chief Operating Officer Jul 12, 2022 InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance Jun 14, 2022 InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions Jun 09, 2022 InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector Jun 06, 2022 InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules Jun 02, 2022 InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules May 13, 2022 InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 05, 2022 InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Apr 28, 2022 InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 210 Investor Alerts Sign up for investor alerts! Sign Up Information Request Send us a request for information Learn More
Press Releases Year None20222021202020192018201720162015 Jul 25, 2022 InMed Announces Update on Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa Jul 18, 2022 InMed Announces Appointment of Chief Operating Officer Jul 12, 2022 InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance Jun 14, 2022 InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions Jun 09, 2022 InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector Jun 06, 2022 InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules Jun 02, 2022 InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules May 13, 2022 InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update May 05, 2022 InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV Apr 28, 2022 InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 10 of 210